12 news items
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, and Li Auto and Encourages Investors to Contact the Firm
AXTI
INTC
LI
22 May 24
phase of sales by shifting its focus toward its core user group, target sales to cities with stronger purchasing power, and then will look to expand
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, and Li Auto and Encourages Investors to Contact the Firm
AXTI
INTC
LI
18 May 24
that it will revert to the validation phase of sales by shifting its focus toward its core user group, target sales to cities with stronger purchasing power
Assessing AXT: Insights From 10 Financial Analysts
AXTI
3 May 24
0
Analysts have set 12-month price targets for AXT, revealing an average target of $5.11, a high estimate of $6.00
Wedbush Reiterates Outperform on AXT, Maintains $6 Price Target
AXTI
3 May 24
Wedbush analyst Matt Bryson reiterates AXT (NASDAQ:AXTI) with a Outperform and maintains $6 price target.
Needham Reiterates Buy on AXT, Maintains $5 Price Target
AXTI
3 May 24
Needham analyst Charles Shi reiterates AXT (NASDAQ:AXTI) with a Buy and maintains $5 price target.
f04uxgk25m7lgzgtm650x3z8u7zj
AXTI
9 Apr 24
Craig-Hallum analyst Richard Shannon maintains AXT (NASDAQ:AXTI) with a Buy and raises the price target from $3.75 to $5.
thl9378z iiwkp8sydhozyitmrx0bqays8p0n
AXTI
9 Apr 24
Needham analyst Charles Shi reiterates AXT (NASDAQ:AXTI) with a Buy and maintains $5 price target.
jb38si2e
AEHL
AGEN
AIRC
8 Apr 24
Thibault initiated coverage on Outset Medical with a Buy rating and announced a price target of $6.
Dogness (International
tmz12po59a pdcs7buvn7
AXTI
8 Apr 24
Wedbush analyst Matt Bryson maintains AXT (NASDAQ:AXTI) with a Outperform and maintains $6 price target.
pza7fvrkax7wp h4g6atu0zvpla
AXTI
5 Apr 24
of 12-month price targets, revealing an average target of $4.81, a high estimate of $6.00, and a low estimate of $3.75. Observing a 70.57% increase
e2bbkn13lgwvqp
AXTI
5 Apr 24
B. Riley Securities analyst Dave Kang maintains AXT (NASDAQ:AXTI) with a Buy and raises the price target from $3.8 to $5.5.
hl8 91i7kctd3a
ABIO
ACHL
ADXN
4 Apr 24
with a Buy rating and announced a $5 price target.
Tevogen Bio Holdings Inc
- Prev
- 1
- Next